Claude Knopf, a former Novartis executive, has joined ImCheck Therapeutics SAS of Marseille, France as chief business officer. He will be located in Boston, US. ImCheck is developing antibody drug candidates targeting the butyrophilin superfamily of immune system regulators.
Mr Knopf was most recently CBO at Gemini Therapeutics Inc and Pieris Pharmaceuticals Inc. Prior to this, he led business development and mergers and acquisition activity at Baxter BioScience and its 2015 spin-out Baxalta Inc. Mr Knopf holds a master’s degree in international business from the Moore School of Business at the University of South Carolina and a BA in economics from Manchester College, both in the US.
ImCheck announced the appointment on 9 July 2020.
Copyright 2020 Evernow Publishing Ltd